Last reviewed · How we verify
Ocrelizumab Test Formulation
Ocrelizumab Test Formulation is an investigational subcutaneous formulation variant of Hoffmann-La Roche's ocrelizumab, a CD20-targeting monoclonal antibody approved for multiple sclerosis and certain B-cell malignancies. The drug works by selectively binding to CD20 on B-cell surfaces, leading to B-cell depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Currently in Phase 2 development, this test formulation is being evaluated for bioequivalence against the established intravenous formulation in a 182-patient MS trial, with the goal of improving patient convenience and treatment adherence through subcutaneous administration. Ocrelizumab (Ocrevus) generated approximately $3.2B in global revenue in 2023, making it one of Roche's key immunology assets; this formulation development represents a strategic effort to expand the drug's commercial footprint by addressing patient preference for self-administered therapies. The subcutaneous route could differentiate this formulation from competitors like natalizumab and fingolimod in the MS market, potentially unlocking new patient segments and improving long-term market penetration.
At a glance
| Generic name | Ocrelizumab Test Formulation |
|---|---|
| Also known as | RO4964913 |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ocrelizumab Test Formulation CI brief — competitive landscape report
- Ocrelizumab Test Formulation updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI